Biomarkers: Where to Go from Here.
作者信息
Paradiso Angelo
机构信息
National Cancer Research Center, Istituto Tumori 'Giovanni Paolo II', Bari, Italy.
出版信息
Breast Care (Basel). 2012 Feb;7(1):5-6. doi: 10.1159/000337179. Epub 2012 Feb 23.
Abstract
摘要
相似文献
1
Biomarkers: Where to Go from Here.生物标志物：路在何方。
Breast Care (Basel). 2012 Feb;7(1):5-6. doi: 10.1159/000337179. Epub 2012 Feb 23.
2
Blood-based biomarkers in Alzheimer disease: where are we now and where have we to go?阿尔茨海默病的血液生物标志物：我们现在处于什么阶段，又将何去何从？
JAMA Neurol. 2013 Jan;70(1):133. doi: 10.1001/2013.jamaneurol.67.
3
Usefulness of TSH receptor antibodies as biomarkers for Graves' ophthalmopathy: a systematic review.促甲状腺素受体抗体作为格雷夫斯眼病生物标志物的效用：系统评价。
J Endocrinol Invest. 2018 Dec;41(12):1457-1468. doi: 10.1007/s40618-018-0945-6. Epub 2018 Sep 7.
4
Blood-based biomarkers in Alzheimer disease: where are we now and where have we to go?-Reply.阿尔茨海默病中基于血液的生物标志物：我们现在所处的位置以及我们要去往何方？-回复
JAMA Neurol. 2013 Jan;70(1):133-4. doi: 10.1001/jamaneurol.2013.709.
5
Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.建立区分伴有或不伴有眼眶病的格雷夫斯病的泪液蛋白质生物标志物组。
PLoS One. 2017 Apr 18;12(4):e0175274. doi: 10.1371/journal.pone.0175274. eCollection 2017.
6
Search of reference biomarkers reflecting orbital tissue remodeling in the course of Graves' orbitopathy.寻找反映格雷夫斯眼眶病病程中眼眶组织重塑的参考生物标志物。
Folia Histochem Cytobiol. 2020;58(1):37-45. doi: 10.5603/FHC.a2020.0003. Epub 2020 Mar 16.
7
Role of binding immunoglobulin protein (BiP) in Graves' orbitopathy pathogenesis.结合免疫球蛋白蛋白（BiP）在格雷夫斯眼眶病发病机制中的作用。
J Mol Endocrinol. 2021 Jan;66(1):71-81. doi: 10.1530/JME-20-0155.
8
Comparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathy.伴有和不伴有眼眶病变的格雷夫斯病患者泪液的比较蛋白质组学分析。
Clin Endocrinol (Oxf). 2016 Nov;85(5):805-812. doi: 10.1111/cen.13122. Epub 2016 Jul 1.
9
Inflammatory bowel diseases: where we are and where we should go.炎症性肠病：我们所处的位置以及我们应前往的方向。
Clin Chem Lab Med. 2014 Apr;52(4):463-5. doi: 10.1515/cclm-2014-0146.
10
Biomarkers, inflammation and cancer: where to go?生物标志物、炎症与癌症：何去何从？
Clin Chem Lab Med. 2016 Dec 1;54(12):1847-1852. doi: 10.1515/cclm-2016-0769.
本文引用的文献
1
The Discriminatory Value of CYP2D6 Genotyping in Predicting the Dextromethorphan/Dextrorphan Phenotype in Women with Breast Cancer.CYP2D6基因分型在预测乳腺癌女性右美沙芬/右啡烷表型中的鉴别价值
Breast Care (Basel). 2012 Feb;7(1):25-31. doi: 10.1159/000336551. Epub 2012 Feb 20.
2
The 70-Gene Signature as Prognostic Factor for Elderly Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer.70基因特征作为激素受体阳性、HER2阴性老年乳腺癌女性的预后因素
Breast Care (Basel). 2012 Feb;7(1):19-24. doi: 10.1159/000336552. Epub 2012 Feb 13.
3
Analysis of Clinical Features and Outcome of 356 Triple-Negative Breast Cancer Patients in China.中国356例三阴性乳腺癌患者的临床特征及预后分析
Breast Care (Basel). 2012 Feb;7(1):13-17. doi: 10.1159/000336539. Epub 2012 Feb 13.
4
Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.转移性乳腺癌患者外周血循环肿瘤细胞的多标志物分析：个性化医疗的一大进步。
Breast Care (Basel). 2012 Feb;7(1):7-12. doi: 10.1159/000336548. Epub 2012 Feb 21.
5
The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.EORTC 10041/BIG 03-04 MINDACT 试验是可行的：试验前期的结果。
Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1.
6
Medical oncology: clinical value of circulating tumor cells in breast cancer.医学肿瘤学：循环肿瘤细胞在乳腺癌中的临床价值
Nat Rev Clin Oncol. 2011 Nov 1;8(12):696-8. doi: 10.1038/nrclinonc.2011.167.
7
The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.CYP2D6 基因分型用于管理接受他莫昔芬治疗的乳腺癌女性的临床效果和成本效益：系统评价。
Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330.
8
Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study.中国女性乳腺癌分子亚型的独特分布及其预后意义：一项基于人群的队列研究。
BMC Cancer. 2011 Jul 12;11:292. doi: 10.1186/1471-2407-11-292.
Zotero 插件